A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Percentage of Participants With Protocol-defined Influenza-like Illness (ILI) With Confirmed Influenza A (by Reverse Transcription Polymerase Chain Reaction [RT-PCR])

Protocol-defined ILI with confirmed influenza A defined as RT-PCR confirmed influenza A with at least one respiratory symptom and at least one systemic symptom

Time frame: Up to 24 Weeks

Number of Participants With Adverse Events (AEs)

Time frame: Up to 26 Weeks

Number of Participants With Serious Adverse Events (SAEs)

Time frame: Up to 26 Weeks

Number of Participants With Adverse Events of Special Interest (AESI)

AESI is anaphylaxis per MedDRA anaphylaxis algorithmic SMQ

Time frame: Up to 26 Weeks

Number of Participants With Vital Sign Abnormalities

Defined as a graded abnormality in systolic blood pressure, diastolic blood pressure, pulse, respiratory rate, or oral temperature as per the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials at any time on/after receipt of study intervention.

Time frame: Up to 26 Weeks

Number of Participants With Clinical Laboratory Abnormalities

Defined as graded abnormality in chemistry, hematology, liver function, or urinalysis clinical laboratory values as per the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Trials at any time on/after receipt of study intervention.

Time frame: Up to 26 Weeks

Number of Participants With Solicited Injection Site Reactions

Injection site reactions from the study intervention diary card

Time frame: Up to Day 7 following study intervention administration